Wedbush Analysts Decrease Earnings Estimates for FENC

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Investment analysts at Wedbush lowered their FY2025 earnings per share estimates for Fennec Pharmaceuticals in a note issued to investors on Thursday, November 7th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.05 for the year, down from their prior forecast of $0.06. Wedbush currently has a "Outperform" rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.08 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' FY2026 earnings at $2.25 EPS.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.26). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 53.38%. The firm had revenue of $7.26 million during the quarter, compared to analyst estimates of $13.67 million. During the same period in the prior year, the business posted ($0.21) EPS.

FENC has been the topic of a number of other research reports. HC Wainwright dropped their target price on Fennec Pharmaceuticals from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, August 22nd. Craig Hallum reduced their target price on Fennec Pharmaceuticals from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday, August 14th.

Fennec Pharmaceuticals Stock Down 0.7 %

Fennec Pharmaceuticals stock traded down $0.03 during midday trading on Monday, reaching $4.26. The stock had a trading volume of 112,686 shares, compared to its average volume of 113,069. The firm's fifty day simple moving average is $4.84 and its 200-day simple moving average is $6.09. Fennec Pharmaceuticals has a 1-year low of $3.98 and a 1-year high of $11.92. The stock has a market capitalization of $116.85 million, a P/E ratio of 106.53 and a beta of 0.27. The company has a debt-to-equity ratio of 9.86, a quick ratio of 7.75 and a current ratio of 8.02.

Hedge Funds Weigh In On Fennec Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FENC. Bank of New York Mellon Corp grew its position in Fennec Pharmaceuticals by 42.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company's stock worth $420,000 after acquiring an additional 20,602 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Fennec Pharmaceuticals by 71,275.0% in the 1st quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company's stock valued at $381,000 after buying an additional 34,212 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Fennec Pharmaceuticals in the 2nd quarter valued at about $49,000. WINTON GROUP Ltd bought a new stake in shares of Fennec Pharmaceuticals in the 2nd quarter valued at about $409,000. Finally, Rhumbline Advisers grew its position in shares of Fennec Pharmaceuticals by 44.7% in the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company's stock valued at $178,000 after buying an additional 8,987 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.